

## DEINOVE ANNOUNCES THE COMPLETION OF ITS SHARE CAPITAL INCREASE WITH SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS

**Montpellier, 23 December 2015** – DEINOVE (Alternext Paris: ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals from non-food biomass with its *Deinococcus* bacteria, announced today the completion of the capital increase with preferential subscription rights amounting to 10,667,862 euros with the issuance of 2,370,636 new shares (1,873,590 new shares subscribed on an irreducible basis and 497,046 new shares on a reducible basis).

In the face of the high demand, the funds managed by Truffle Capital have finally subscribed 71,199 new shares amounting to 320,395.50 euros.

The Company's share capital henceforth amounts to 3,421,962.80 euros, represented by 8,554,907 shares with a par value of 0.40 euro each.

### Shareholding structure post-capital increase (to the Company's knowledge)

Shareholders	Number of shares	Holding percentage	Voting rights	Percentage
Funds managed by Truffle Capital	2,828,215	33.06%	5,493,433	48.37%
Tereos EU	118,685	1.39%	118,685	1.05%
Scientific founders	20,000	0.23%	40,000	0.35%
Management & Board members	58,949	0.69%	77,690	0.68%
Floating	5,529,058	64.63%	5,646,445	49.54%
<b>TOTAL</b>	<b>8,554,907</b>	<b>100.00%</b>	<b>11,356,253</b>	<b>100.00%</b>

The share capital increase with shareholders' preferential subscription rights was led by SwissLife Private Banking acting as Lead Manager and Bookrunner of the transaction. Brunswick Société d'Avocats was DEINOVE's counsel for the legal aspects of the operation.

NOT TO BE PUBLISHED, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY,  
IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA

## About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the *Deinococci*. Taking advantage of the bacteria's unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company's primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.

Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs almost 50 people in its offices and laboratories located in Montpellier, France.

*More information at [www.deinove.com](http://www.deinove.com)*

### Contacts DEINOVE

#### **Emmanuel Petiot**

CEO

Tel.: +33 (0)4 48 19 01 28

[emmanuel.petiot@deinove.com](mailto:emmanuel.petiot@deinove.com)

#### **Coralie Martin**

Communication, Marketing and IR Manager

Tel.: +33 (0)4 48 19 01 60

[coralie.martin@deinove.com](mailto:coralie.martin@deinove.com)

### ALIZE RP, Press Relations

#### **Caroline Carmagnol / Wendy Rigal**

Tel.: +33 (0)1 44 54 36 66

[deinove@alizerp.com](mailto:deinove@alizerp.com)



## Disclaimer

The offer was opened to the public in France.

The prospectus approved by the French Financial Markets Authority (the "AMF") on November 26, 2015 under number 15-607 includes DEINOVE's Document de Reference (the "Registration Document"), registered with the AMF on November 26, 2015 under number R.15-081, a securities note (the "Securities Note") and a summary of the prospectus (included in the securities note).

- **Availability of the reference document:** copies of the prospectus are available free of charge from DEINOVE, 1682, rue de la Valsière – Cap Sigma, ZAC Euromédecine II – 34790 Grabels – France ([www.deinove.com](http://www.deinove.com)) and from the AMF website ([www.amf-france.org](http://www.amf-france.org)).
- **Risk factors:** DEINOVE wishes to draw the public's attention to chapter 4 (Risk factors) of the registration document filed with the AMF and to section 2 (Risk factors) of the Securities Note.

This press release and the prospectus registered with the French Financial Markets Authority (Autorité des marchés financiers) contain forward-looking statements. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in the prospectus, and to the development of economic conditions, the financial markets and the markets in which DEINOVE operates.

---

NOT TO BE PUBLISHED, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY,  
IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA

#### European Economic Area

The offer was opened to the public in France.

With respect to members of the European Economic Area other than France (the “Member States”) that have implemented the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of securities requiring the publication of a prospectus in any Member State. Therefore, the Rights, the new shares and other securities mentioned in this press release may only be offered in Member States:

- to qualified investors as defined in the Prospectus Directive;
- to less than 100 or, if the Member State has transposed the relevant provision amending the Prospectus Directive, 150 natural or legal persons (other than qualified investors as defined in the Amending Prospectus Directive) per Member State; or
- in circumstances falling under the scope of Article 3 (2) of the Prospectus Directive.

For the purposes of this paragraph, (i) the expression “public offer of securities” in a given Member State means the communication to persons, in any form and by any means whatsoever, and containing sufficient information on the conditions of the offer and the securities to be offered to enable an investor to decide to purchase or subscribe said securities, as that definition has been, where appropriate, modified by the Member State in question, (ii) the expression “Prospectus Directive” means Directive 2003/71/EC of November 4, 2003, as transposed into the law of the Member State in question (as amended, including the Amending Prospective Directive when it has been transposed by each Member State), and (iii) the expression “Amending Prospectus Directive” means Directive 2010/73/EU of the European Parliament and of the Council of November 24, 2010. These sales restrictions relating to Member States apply in addition to any other restrictions applicable in Member States that have transposed the Prospectus Directive.

#### United Kingdom

This press release does not contain or constitute an invitation, inducement or solicitation to invest. This press release is intended solely for persons (i) who are not in the United Kingdom, (ii) who are investment professionals within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”), (iii) who are persons falling within the provisions of Article 49 (2) (a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iv) who are persons to whom an invitation or inducement to engage in investment activity (within the meaning of the Financial Services and Markets Act 2000) may lawfully be made or caused to be made in the context of the issuance or sale of securities (all persons cited in (i), (ii), (iii) and (iv) together being designated as “Relevant Persons”).

This press release is aimed solely at Relevant Persons, and must not be used or relied upon by unauthorized persons. Any investment or investment activity in connection with this press release is reserved solely for Relevant Persons, and may only be made by Relevant Persons. This press release does not constitute an approval by the Financial Services Authority or any other regulatory authority in the United Kingdom within the meaning of Section 85 of the Financial Services and Markets Act 2000.

#### United States of America

This press release does not constitute an offer to sell securities or the solicitation of an offer to purchase securities in the United States of America. The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States in the absence of registration or an exemption from registration under the Securities Act. DEINOVE does not intend to register the offer in whole or in part in the United States of America, or to make a public offer in the United States of America.

---

NOT TO BE PUBLISHED, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY,  
IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA